Literature DB >> 12355360

Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.

Nancy Dumais1, Amy Patrick, Ronald B Moss, Heather L Davis, Kenneth L Rosenthal.   

Abstract

Vaccines capable of protecting against sexually transmitted infections, such as human immunodeficiency virus (HIV), will depend on the induction of potent long-lasting mucosal immune responses in the genital tract. We evaluated vaginal and systemic immune responses and protection from vaginal challenge elicited after intranasal immunization of mice with inactivated glycoprotien 120-depleted HIV-1 immunogen alone or in combination with immunostimulatory CpG oligodeoxynucleotides (ODNs). Mice immunized with HIV-1 immunogen plus CpG ODN had significantly enhanced levels of anti-protein 24 immunoglobulin (Ig) G and IgA antibodies in serum and vaginal washes and increased production of beta-chemokines and interferon-gamma, compared with mice immunized with HIV-1 immunogen alone or with control ODN. Furthermore, mice intranasally immunized with HIV-1 immunogen plus CpG were protected against intravaginal challenge with a recombinant vaccinia virus expressing HIV-1 gag. These results indicate that mucosal immunization with whole-killed HIV-1 plus CpG ODN may be an effective means of inducing local immunity and protection against genital infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12355360     DOI: 10.1086/344232

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag.

Authors:  Xinyan Zhao; Manxin Zhang; Zhongxia Li; Fred R Frankel
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides.

Authors:  Janina Q Jiang; Amy Patrick; Ronald B Moss; Kenneth L Rosenthal
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection.

Authors:  Christopher S Eickhoff; Olivia K Giddings; Nobuko Yoshida; Daniel F Hoft
Journal:  Mem Inst Oswaldo Cruz       Date:  2010-08       Impact factor: 2.743

5.  Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha.

Authors:  Jason D Marshall; Darren S Heeke; Christi Abbate; Priscilla Yee; Gary Van Nest
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

6.  Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs.

Authors:  Sunil K Khattar; Sweety Samal; Anthony L Devico; Peter L Collins; Siba K Samal
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

7.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

8.  Tweaking Innate Immunity: the Promise of Innate Immunologicals As Anti-infectives.

Authors:  Kenneth L Rosenthal
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-09       Impact factor: 2.471

9.  Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.

Authors:  John W Mapletoft; Laura Latimer; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

10.  A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge.

Authors:  X Zhang; A A Chentoufi; G Dasgupta; A B Nesburn; M Wu; X Zhu; D Carpenter; S L Wechsler; S You; L BenMohamed
Journal:  Mucosal Immunol       Date:  2008-12-24       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.